Overall, utilizing agents that target both Akt and mTOR, causing both a reduction in the phosphorylated/activated and total levels of these proteins, may result in cancer cells becoming more sensitized to treatments and reducing drug resistance. This evidence concerns the gene AKT1 and cancer.